vs
Side-by-side financial comparison of Phillips Edison & Company, Inc. (PECO) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $190.7M, roughly 1.6× Phillips Edison & Company, Inc.). Phillips Edison & Company, Inc. runs the higher net margin — 17.4% vs 16.4%, a 1.0% gap on every dollar of revenue. On growth, Phillips Edison & Company, Inc. posted the faster year-over-year revenue change (7.0% vs -1.5%). Over the past eight quarters, Phillips Edison & Company, Inc.'s revenue compounded faster (8.7% CAGR vs 1.3%).
Consolidated Edison, Inc., commonly known as Con Edison or ConEd, is an energy company based in New York City. It is one of the largest investor-owned energy companies in the United States, with approximately $15.26 billion in annual revenues as of 2024, and over $70 billion in assets. The company provides a wide range of energy-related products and services to its customers through its subsidiaries:Consolidated Edison Company of New York, Inc. (CECONY), a regulated utility providing electric...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
PECO vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $190.7M | $311.4M |
| Net Profit | $33.2M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | 30.5% | 24.2% |
| Net Margin | 17.4% | 16.4% |
| Revenue YoY | 7.0% | -1.5% |
| Net Profit YoY | 15.1% | 126.0% |
| EPS (diluted) | $0.24 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $190.7M | $311.4M | ||
| Q4 25 | $187.9M | $295.9M | ||
| Q3 25 | $182.7M | — | ||
| Q2 25 | $177.8M | $317.0M | ||
| Q1 25 | $178.3M | $316.2M | ||
| Q4 24 | $173.0M | $297.0M | ||
| Q3 24 | $165.5M | $289.5M | ||
| Q2 24 | $161.5M | $306.1M |
| Q1 26 | $33.2M | $51.0M | ||
| Q4 25 | $47.5M | $38.0M | ||
| Q3 25 | $24.7M | — | ||
| Q2 25 | $12.8M | $-17.7M | ||
| Q1 25 | $26.3M | $22.6M | ||
| Q4 24 | $18.1M | $34.9M | ||
| Q3 24 | $11.6M | $33.6M | ||
| Q2 24 | $15.3M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | 30.5% | 24.2% | ||
| Q4 25 | — | 18.4% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 15.0% |
| Q1 26 | 17.4% | 16.4% | ||
| Q4 25 | 25.3% | 12.8% | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 7.2% | -5.6% | ||
| Q1 25 | 14.8% | 7.1% | ||
| Q4 24 | 10.5% | 11.7% | ||
| Q3 24 | 7.0% | 11.6% | ||
| Q2 24 | 9.5% | 13.3% |
| Q1 26 | $0.24 | $0.32 | ||
| Q4 25 | $0.38 | $0.24 | ||
| Q3 25 | $0.20 | — | ||
| Q2 25 | $0.10 | $-0.11 | ||
| Q1 25 | $0.21 | $0.14 | ||
| Q4 24 | $0.16 | $0.22 | ||
| Q3 24 | $0.09 | $0.21 | ||
| Q2 24 | $0.12 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.1M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $2.1B |
| Total Assets | $5.4B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.1M | $209.8M | ||
| Q4 25 | $3.5M | $172.9M | ||
| Q3 25 | $4.1M | — | ||
| Q2 25 | $5.6M | $162.2M | ||
| Q1 25 | $5.5M | $140.7M | ||
| Q4 24 | $4.9M | $177.5M | ||
| Q3 24 | $6.4M | $187.5M | ||
| Q2 24 | $7.1M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $260.0M | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | $346.0M | ||
| Q1 25 | $2.3B | $330.0M | ||
| Q4 24 | $2.1B | $300.0M | ||
| Q3 24 | $2.1B | $300.0M | ||
| Q2 24 | $2.0B | $319.0M |
| Q1 26 | $2.3B | $2.1B | ||
| Q4 25 | $2.3B | $2.0B | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | $1.9B | ||
| Q1 25 | $2.3B | $2.0B | ||
| Q4 24 | $2.3B | $2.1B | ||
| Q3 24 | $2.2B | $2.1B | ||
| Q2 24 | $2.3B | $2.1B |
| Q1 26 | $5.4B | $2.6B | ||
| Q4 25 | $5.3B | $2.5B | ||
| Q3 25 | $5.3B | — | ||
| Q2 25 | $5.3B | $2.6B | ||
| Q1 25 | $5.2B | $2.6B | ||
| Q4 24 | $5.0B | $2.7B | ||
| Q3 24 | $5.0B | $2.7B | ||
| Q2 24 | $4.9B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 1.04× | 0.13× | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 1.04× | 0.18× | ||
| Q1 25 | 0.99× | 0.16× | ||
| Q4 24 | 0.91× | 0.14× | ||
| Q3 24 | 0.94× | 0.14× | ||
| Q2 24 | 0.90× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $55.6M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 12.6% | — |
| Cash ConversionOCF / Net Profit | 1.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $55.6M | — | ||
| Q4 25 | $348.1M | — | ||
| Q3 25 | $95.4M | — | ||
| Q2 25 | $96.1M | $98.2M | ||
| Q1 25 | $60.5M | $41.1M | ||
| Q4 24 | $334.7M | $84.3M | ||
| Q3 24 | $109.1M | $63.9M | ||
| Q2 24 | $78.5M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% |
| Q1 26 | 12.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% |
| Q1 26 | 1.67× | — | ||
| Q4 25 | 7.33× | — | ||
| Q3 25 | 3.87× | — | ||
| Q2 25 | 7.52× | — | ||
| Q1 25 | 2.30× | 1.82× | ||
| Q4 24 | 18.45× | 2.42× | ||
| Q3 24 | 9.40× | 1.90× | ||
| Q2 24 | 5.14× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PECO
| Rental income | $186.3M | 98% |
| Fees and management income | $3.4M | 2% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
